Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 6/20/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong David Hallal?

David L. Hallal

Chief Executive Officer

Alexion Pharmaceuticals Inc

HQ Phone:  (203) 272-2596

Direct Phone: (203) ***-****direct phone

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Alexion Pharmaceuticals Inc

100 College Street

New Haven, Connecticut,06510

United States

Company Description

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion is the global leader in complement inhibition and has developed and commercializes the firs...more

Web References(120 Total References)


www.alexion.com

"Alexion was founded 24 years ago in New Haven, and we are pleased to be back here establishing our global headquarters with a commitment to supporting vital economic, social and environmental efforts in our community," said David Hallal, Chief Executive Officer of Alexion.


phrma.org

David Hallal
Chief Executive Officer Alexion Pharmaceuticals, Inc. Read More


alexion.com [cached]

David Hallal, Chief Executive Officer
David Hallal, Alexion - Chief Executive Officer David Hallal is Chief Executive Officer of Alexion and a member of the company's Board of Directors.. Mr. Hallal was appointed Alexion's second CEO in its 24-year history in April 2015, leading the company to expand its position as the global leader in rare diseases through an important acquisition and the approvals and launches of two highly innovative products. Prior to becoming CEO, Mr. Hallal was Chief Operating Officer, leading strategic enterprise-wide initiatives that focused on diverse aspects of Alexion's business, including the expansion of the company's research and development pipeline and manufacturing operations. Previously, Mr. Hallal was Alexion's first Chief Commercial Officer. Mr. Hallal joined Alexion in 2006 to build the company's commercial operations and he led the successful introduction of Soliris ® (eculizumab), the company's first product for two ultra-rare diseases. He played a principal role in leading many significant growth initiatives including the development of Alexion's 50-country operating platform. In addition to his leadership of all global commercial operations, Mr. Hallal has been responsible for country operations in each of Alexion's affiliates in Europe/Middle East/Africa (EMEA), Japan, Australasia, and Latin America. Mr. Hallal has more than 25 years of experience in the biopharmaceutical industry. Before joining Alexion, he advanced through positions of increasing responsibility in sales, marketing and management at Amgen, Biogen, and OSI Eyetech directing product launches in the areas of hematology, oncology, nephrology and immunology. Mr. Hallal is a member of the Board of Directors of the Pharmaceutical Research and Manufacturers of America and the Biotechnology Industry Organization. He holds a Bachelor of Arts degree from the University of New Hampshire. David Hallal, Chief Executive Officer David Hallal is Chief Executive Officer of Alexion. Prior to becoming CEO, Mr. Hallal was Chief Operating Officer, leading strategic enterprise-wide initiatives that focused on diverse aspects of Alexion's operations. He also has served on all key management decision-making committees, and in September 2014 was elected to the Company's Board of Directors. Previously, Mr. Hallal was Alexion's first Chief Commercial Officer. Mr. Hallal joined Alexion in 2006 to launch the company's commercial operations. He played a principal role in leading many of the company's major growth initiatives and led the highly successful introductions of Soliris® (eculizumab) for both PNH and aHUS, while also building Alexion's 50-country operating platform. In addition to his leadership of all commercial operations globally, Mr. Hallal has been responsible for country operations in each of Alexion's affiliates in Europe/Middle East/Africa (EMEA), Japan, Australasia, and Latin America. Mr. Hallal has more than 25 years of experience in the biopharmaceutical industry. Before joining Alexon, he held commercial leadership positions at OSI Eyetech, Biogen Idec and Amgen where he was involved in multiple blockbuster product launches in the areas of hematology, oncology, nephrology and immunology. Mr. Hallal holds a BA from the University of New Hampshire.


ir.alexionpharm.com [cached]

David Hallal
Chief Executive Officer David Hallal David Hallal is Chief Executive Officer of Alexion. Prior to becoming CEO, Mr. Hallal was Chief Operating Officer, leading strategic enterprise-wide initiatives that focused on diverse aspects of Alexion's operations. He also has served on all key management decision-making committees, and in September 2014 was elected to the Company's Board of Directors. Previously, Mr. Hallal was Alexion's first Chief Commercial Officer. Mr. Hallal joined Alexion in 2006 to launch the company's commercial operations. He played a principal role in leading many of the company's major growth initiatives and led the highly successful introductions of Soliris® (eculizumab) for both PNH and aHUS, while also building Alexion's 50-country operating platform. In addition to his leadership of all commercial operations globally, Mr. Hallal has been responsible for country operations in each of Alexion's affiliates in Europe/Middle East/Africa (EMEA), Japan, Australasia, and Latin America. Mr. Hallal has more than 25 years of experience in the biopharmaceutical industry. Before joining Alexion, he held commercial leadership positions at OSI Eyetech, Biogen Idec and Amgen where he was involved in multiple blockbuster product launches in the areas of hematology, oncology, nephrology and immunology. Mr. Hallal holds a BA from the University of New Hampshire.


alexionpharm.com [cached]

David Hallal, Chief Executive Officer
David Hallal, Alexion - Chief Executive Officer David Hallal is Chief Executive Officer of Alexion. Prior to becoming CEO, Mr. Hallal was Chief Operating Officer, leading strategic enterprise-wide initiatives that focused on diverse aspects of Alexion's operations. He also has served on all key management decision-making committees, and in September 2014 was elected to the Company's Board of Directors. Previously, Mr. Hallal was Alexion's first Chief Commercial Officer. Mr. Hallal joined Alexion in 2006 to launch the company's commercial operations. He played a principal role in leading many of the company's major growth initiatives and led the highly successful introductions of Soliris® (eculizumab) for both PNH and aHUS, while also building Alexion's 50-country operating platform. In addition to his leadership of all commercial operations globally, Mr. Hallal has been responsible for country operations in each of Alexion's affiliates in Europe/Middle East/Africa (EMEA), Japan, Australasia, and Latin America. Mr. Hallal has more than 25 years of experience in the biopharmaceutical industry. Before joining Alexion, he held commercial leadership positions at OSI Eyetech, Biogen Idec and Amgen where he was involved in multiple blockbuster product launches in the areas of hematology, oncology, nephrology and immunology. Mr. Hallal holds a BA from the University of New Hampshire. David Hallal, Chief Executive Officer David Hallal is Chief Executive Officer of Alexion. Prior to becoming CEO, Mr. Hallal was Chief Operating Officer, leading strategic enterprise-wide initiatives that focused on diverse aspects of Alexion's operations. He also has served on all key management decision-making committees, and in September 2014 was elected to the Company's Board of Directors. Previously, Mr. Hallal was Alexion's first Chief Commercial Officer. Mr. Hallal joined Alexion in 2006 to launch the company's commercial operations. He played a principal role in leading many of the company's major growth initiatives and led the highly successful introductions of Soliris® (eculizumab) for both PNH and aHUS, while also building Alexion's 50-country operating platform. In addition to his leadership of all commercial operations globally, Mr. Hallal has been responsible for country operations in each of Alexion's affiliates in Europe/Middle East/Africa (EMEA), Japan, Australasia, and Latin America. Mr. Hallal has more than 25 years of experience in the biopharmaceutical industry. Before joining Alexon, he held commercial leadership positions at OSI Eyetech, Biogen Idec and Amgen where he was involved in multiple blockbuster product launches in the areas of hematology, oncology, nephrology and immunology. Mr. Hallal holds a BA from the University of New Hampshire.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory